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Although the CDH13 gene has been shown to undergo epigenetic
silencing by promoter methylation in many types of tumors, hy-
permethylation of this gene in Barrett’s-associated esophageal
adenocarcinogenesis has not been studied. Two hundred fifty-nine
human esophageal tissues were therefore examined for CDH13
promoter hypermethylation by real-time methylation-specific
PCR. CDH13 hypermethylation showed discriminative receiver-
operator characteristic curve profiles, sharply demarcating esopha-
geal adenocarcinoma (EAC) from esophageal squamous cell carci-
noma (ESCC) and normal esophagus (NE) (p < 0.0001). CDH13
normalized methylation values (NMV) were significantly higher in
Barrett’s esophagus (BE), dysplastic BE (D) and EAC than in NE
(p < 0.0000001). CDH13 hypermethylation frequency was 0% in
NE but increased early during neoplastic progression, rising to
70% in BE, 77.5% in D and 76.1% in EAC. Both CDH13 hyper-
methylation frequency and its mean NMV were significantly
higher in BE with than without accompanying EAC. In contrast,
only 5 (19.2%) of 26 ESCCs exhibited CDH13 hypermethylation.
Furthermore, both CDH13 hypermethylation frequency and its
mean NMV were significantly higher in EAC than in ESCC, as
well as in BE or D vs. ESCC. Interestingly, mean CDH13 NMV
was significantly lower in short-segment than in long-segment BE,
a known clinical risk factor for neoplastic progression. Similarly,
BE segment length was significantly lower in specimens with
unmethylated than with methylated CDH13 promoters. 5-aza-20-
deoxycytidine treatment of OE33 EAC and KYSE220 ESCC cells
reduced CDH13methylation and increased CDH13mRNA expres-
sion. These findings suggest that hypermethylation of CDH13 is a
common, tissue-specific event in human EAC, occurs early during
BE-associated neoplastic progression, and correlates with known
clinical neoplastic progression risk factors.
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CDH13 (also known as H-cadherin and T-cadherin), a member
of the cadherin gene superfamily, was isolated and has been
mapped to 16q24,1 a locus that frequently undergoes deletion in
human cancers, including esophageal carcinoma.2,3 In contrast to
other known cadherins such as E-cadherin, N-cadherin and P-cad-
herin, which are transmembrane proteins, CDH13 lacks conven-
tional transmembrane and cytoplasmic domains and is attached to
the plasma membrane through a glycosyl phosphatidyl inositol
anchor.1,4–6 Several studies have suggested that CDH13 functions
as a tumor suppressor gene and possesses potent antitumor acti-
vity in several human cancers both in vitro and in vivo.7–10 Over-
expression of CDH13 in human breast carcinoma cells
(MDAMB435) reduced their invasive potential in vitro and tumor
formation in vivo, accompanied by reversion from invasive to nor-
mal cell morphology.7 Loss of CDH13 protein expression is asso-
ciated with tumorigenicity of human non-small cell lung cancer
cells.8,9 In cutaneous squamous cell carcinoma cells, overexpres-
sion of CDH13 induced a delay in the G2/M phase of the cell cycle
and reduced cell proliferation.10 Downregulation of CDH13
expression has been reported in various human cancers, including
those arising in the breast, lung, ovary, stomach and colon.1,8,9,11–14
It is now well-established that promoter hypermethylation
correlates with silencing of gene transcription in many cancers,15
including ESCC and EAC.16–18 Furthermore, there is a growing
body of evidence showing that abnormal methylation of DNA can
be an early event in carcinogenesis and can serve as an early can-
cer detection biomarker,15 including in EAC.17–20 Hypermethyl-
ation of CDH13 has been described in many human can-
cers,8,14,21–29 including ESCC24,29; however, hypermethylation of
CDH13 in precancerous lesions such as Barrett’s metaplasia (BE),
as well as in BE-associated EAC, is an area that still remains to be
explored. We investigated hypermethylation of the CDH13 pro-
moter by real-time quantitative methylation-specific PCR (qMSP)
in 259 endoscopic esophageal biopsy specimens of differing
histologies and correlated these data with clinicopathological
features. Our results reveal that promoter hypermethylation of
CDH13 is a common event in EAC but not in ESCC and occurs
early during BE-associated esophageal neoplastic progression,




The 259 specimens examined in the current study comprised 66
from normal esophagus (NE), 60 of non-dysplastic Barrett’s meta-
plasia {BE, including 36 obtained from patients with BE alone
(Ba) and 24 from patients with BE accompanied by EAC (Bt)}, 40
from dysplastic BE {D, including 19 low-grade (LGD) and 21
high-grade (HGD)}, 67 EACs and 26 ESCCs. All patients pro-
vided prior written informed consent under a protocol approved
by the Institutional Review Boards at the University of Maryland
School of Medicine, the Baltimore Veterans Affairs Medical Cen-
ter and the Johns Hopkins University School of Medicine. Biop-
sies were obtained using a standardized biopsy protocol as previ-
ously described.30 Research tissues were taken from grossly appa-
rent BE epithelium or from mass lesions in patients manifesting
these changes at endoscopic examination, and histology was con-
firmed using parallel aliquots culled from identical locations at
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rett’s patient; BE, Barrett’s metaplasia; Bt, BE from EAC patient; EAC,
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LSBE, long-segment BE; MSP, methylation-specific PCR; NE, normal
esophageal epithelium; NMV, normalized methylation value; SSBE, short-
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endoscopy. All research biopsy specimens were stored in liquid
nitrogen prior to DNA extraction. Clinicopathologic characteris-
tics are summarized in Table I.
Cell lines
OE33 EAC and KYSE220 ESCC cells were cultured in 47.5%
RPMI 1640, 47.5% F-12 supplemented with 5% fetal bovine
serum.
DNA and RNA extraction
Genomic DNA was extracted from biopsies and cultured cells
using a DNeasy Tissue Kit (Qiagen, Valencia, CA). Total RNA was
isolated from cultured cells using TRIzol reagent (Invitrogen, Carls-
bad, CA). DNAs and RNAs were stored at280C prior to analysis.
Bisulfite treatment and real-time methylation-specific PCR
One microgram DNA was treated with bisulfite to convert
unmethylated cytosines to uracils prior to MSP using an EpiTect
Bisulfite Kit (Qiagen, Valencia, CA). Promoter methylation levels
of CDH13 were determined by real-time quantitative MSP with an
ABI 7900 Sequence Detection System (Applied Biosystems, Fos-
ter City, CA), using primers and probes as follows: CDH13-for-
ward: 50-TTTGGGAAGTTGGTTGGTTGGC-30; CDH13-reverse:
50-ACTAAAAACGCCCGACGACG-30 and probe: 50-TATGTT
TAGTGTAGTCGCGTGTATGAATGAA-30. b-actin was used
for normalization of data. Primers and probe for b-actin were the
same as previously reported.17 A standard curve was generated
using serial dilutions of CpGenome Universal Methylated DNA
(CHEMICON, Temecula, CA). Normalized methylation value
(NMV) was defined as follows: NMV 5 (CDH13-S/CDH13-FM)/
(ACTB-S/ACTB-FM), where CDH13-S and CDH13-FM represent
CDH13 methylation levels (derived from the standard curve) in
sample and fully methylated DNAs, respectively, while ACTB-S
and ACTB-FM correspond to b-actin in sample and fully methyl-
ated DNAs, respectively.
Real-time quantitiative RT-PCR
To determine CDH13 mRNA levels, one-step real-time quanti-
tative RT-PCR was performed using a Qiagen QuantiTect Probe
RT-PCR Kit (Qiagen, Hilden, Germany) and an ABI 7900
Sequence Detection System (Applied Biosystems, Foster City,
CA). Primers and probe for CDH13 were as follows: CDH13-for-
ward: 50-ATGTTGGCAAGGTAGTCGATAGTG-30; CDH13-
reverse: 50-ACGCTCCCTGTGTTCTCATTG-30 and probe: 50-CC
AGAAAGGTCCAAGTTCCGGCTCACT-30. b-actin was used
for normalization of data. Primers and probe for b-actin were the
same as previously reported.17 A standard curve was generated
using serial dilutions of qPCR Reference Total RNA (Clontech,
Mountainview, CA). Normalized mRNA value (NRV) was calcu-
lated according to the following formula for relative expression
of target mRNA: NRV 5 (TarS/TarC)/(ACTB-S/ACTB-C), where
TarS and TarC represent levels of target gene mRNA expression
(derived from the standard curve) in sample and control mRNAs,
respectively, while ACTB-S and ACTB-C correspond to amplified
ACTB levels in sample and control mRNAs, respectively.
5-Aza-dC treatment of esophageal cancer cell lines
To determine whether CDH13 inactivation was due to promoter
hypermethylation in esophageal cancer, 2 esophageal cancer cell
lines (KYSE220 and OE33) were subjected to 5-Aza-dC (Sigma,
St. Louis, MO) treatment as previously described.31,32 Briefly, 1
3 105 cells/ml were seeded onto a 100-mm dish and grown for
24 hr. Then, 1 ll of 5 mM 5-Aza-dC per ml of cells was added
every 24 hr for 4 days. DNAs and RNAs were harvested on day 4.






NMV2 Methylation Status (cutoff 0.06)3
mean p Frequency UM M p
Histology
Normal esophagus 66 64.3 0.0054 0% 66 0
BE 60 63.7 0.3122 $< 0.00001*/# 70% 18 42
Ba 36 62.5 0.2623 58.3% 15 21 <0.05
Bt 24 65.5 0.3871 $< 0.05 87.5% 3 21
Dysplasia in Barrett’s esophagus 40 65.3 0.3383 $<0.00001*/# 77.5% 9 31
Low-grade dysplasia 19 65.3 0.2833 $< 0.000001* 78.9% 4 15 NS
High-grade dysplasia 21 65.2 0.388 $< 0.000001* 76.2% 5 16
EAC 67 65.1 0.2392 $< 0.00000l*/# 76.1% 16 51 <0.0001
ESCC 26 62.5 0.0458 $<0.01* 19.2% 21 5
Barrett’s segment of Ba
Short-segment (<3cm ) 14 62.3 0.131 $< 0.01 28.6% 10 4 <0.01
Long-segment (>53cm ) 16 62.8 0.4071 87.5% 2 14
Stage of EAC patients
I 7 63 0.3081 –NS 85.7% 1 6 NS
II 15 65.2 0.2408 73.3% 4 11
III 25 64.6 0.2111 72% 7 18
IV 7 66.3 0.2921 100% 0 7
Lymph node metastasis in EAC patients
Negative 25 64.9 0.2751 $NS 75% 5 20 NS
Positive 25 64.6 0.2277 76% 6 19
Smoking status of EAC patients
Never 6 58.5 0.2984 –NS 100% 0 6 NS
Former 24 68.5 0.2143 79.2% 5 19
Current 13 60.8 0.2561 76.9% 3 10
Alcohol drinking status of EAC patients
Never 16 65.3 0.2209 –NS 75% 4 12 NS
Former 15 63 0.2524 86.7% 2 13
Current 10 65.7 0.2427 80% 2 8
1BE, Barrett’s metaplasia; Ba, BE from patients with Barrett’s alone; Bt, BE from patients with Barrett’s accompanied by EA; EAC, esopha-
geal adenocarcinoma; ESCC, esophageal s qua mo us cell carcinoma.–2NMV: normalized methylation value; $Mann-Whitney U test; *compari-
sons made to normal esophagus; #comparisons made to ESCC; –Kruskal-Wallis test.–3UM, unmethylated; M, methylated; Fisher’s exact test;
Chi-square for Independence test.
NS, not significant.
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Data analysis and statistics
Receiver-operator characteristic (ROC) curve analysis33 was
performed using NMVs for the 67 EAC, 26 ESCC and 66 NE
specimens by Analyse-it' software (Version 1.71, Analyse-it
Software, Leeds, UK). Using this approach, the area under the
ROC curve (AUROC) identified optimal sensitivity and specificity
levels at which to distinguish normal from malignant esophageal
tissues (NE vs. EAC), yielding a corresponding NMV threshold
with which to dichotomize the methylation status of CDH13. The
threshold NMV value determined from this ROC curve was
applied to determine the status of CDH13 methylation in all tissue
types included in the study. For all other statistical tests, Statistica
(version 6.1; StatSoft, Tulsa, OK) was employed. Differences with
p < 0.05 were considered significant.
Results
CDH13 promoter hypermethylation in esophageal tissues
Promoter hypermethylation of CDH13 was analyzed in 66 NE,
60 BE (including 36 Ba and 24 Bt), 40 D (including 19 LGD and
21 HGD), 67 EAC, and 26 ESCC. CDH13 promoter hypermethyl-
ation showed highly discriminative ROC curve profiles and
AUROCs, clearly distinguishing both EAC and ESCC from NE
(Figs. 1a and 1b), as well as EAC from ESCC (Fig. 1c).
The cutoff NMV for CDH13 (0.06) was identified from the
ROC curve (EAC vs. NE) to achieve the highest possible sensitiv-
ity while maintaining 100% specificity. Mean NMV and fre-
quency of CDH13 hypermethylation for each tissue type are
shown in Table I. NMVs of CDH13 were significantly higher in
ESCC, EAC, D, HGD, LGD, BE, Ba and Bt than in NE (p <
0.001, Mann–Whitney U test). The frequency of CDH13 hyper-
methylation was significantly higher in BE (70%), D (77.5%) and
EAC (76.1%) than in N (0%; p < 0.0001, p < 0.0001 and p <
0.0001, respectively; Fisher’s exact test). Interestingly, both
CDH13 hypermethylation frequency and mean NMV were signifi-
cantly higher in Bt than in Ba (87.5% vs. 58.3%, p 5 0.021 and
0.3871 vs. 0.2623, p 5 0.045, respectively). The mean CDH13
NMV in EAC (0.2722) was significantly higher than that in
matching NE (0.0034) for 27 cases in which matching NE and
EAC were available (p < 0.00001, Wilcoxon matched pairs test).
In contrast to EAC, only five (19.2%) of 26 ESCCs manifested hy-
permethylation of CDH13. There was no significant difference in
mean CDH13 NMV between tumor and normal tissue in 13 cases
for which matching ESCC (0.0337) and NE (0.0131; p5 0.6, Wil-
coxon matched pairs test) were available. Both CDH13 hyper-
methylation frequency and mean NMV were significantly higher
in EAC than in ESCC (76.1% vs. 19.2%, p < 0.0001 and 0.2392
vs. 0.0458, p < 0.0001, respectively), as well as in D vs. ESCC
(77.5% vs. 19.2%, p < 0.0001 and 0.3383 vs. 0.0458, p < 0.0001,
respectively) and in BE vs. ESCC (70% vs. 19.2%, p < 0.0001
and 0.3122 vs. 0.0458, p < 0.0001; Table I).
According to generally accepted criteria,34 BE was defined as
long-segment (LSBE) if it was equal to or greater than 3 cm in
length, or short-segment (SSBE) if less than 3 cm. The mean
NMV of CDH13 was significantly higher in LSBE than in SSBE
(0.4071 vs. 0.131; p < 0.01, Student’s t-test, Table I and Fig. 2a).
Similarly, segment lengths of BEs with methylated CDH13 pro-
moters (mean 5 5.83 cm) were significantly longer than segment
lengths of BEs with unmethylated CDH13 promoters (mean 5
1.83 cm; p < 0.001, Student’s t-test; Fig. 2b), and the frequency
of CDH13 hypermethylation was significantly higher in LSBE
than in SSBE (87.5% vs. 28.6%; p < 0.01, Fisher’s exact test;
Table I).
No significant associations were observed between CDH13 pro-
moter hypermethylation and patient age (data not shown), survival
(log-rank test, data not shown), tumor stage, lymph node metasta-
sis, smoking or alcohol consumption (Table I).
FIGURE 1 – Receiver-operator characteristic (ROC) curve analysis
of normalized methylation value (NMV). ROC curve analysis of
CDH13 NMVs in esophageal adenocarcinoma (EAC) vs. normal
esophagus (NE) (a), esophageal squamous cell carcinoma (ESCC)
vs. NE (b) and EAC vs. ESCC (c). The high area under the ROC
curve (AUROC) conveys the accuracy of this biomarker in distin-
guishing EAC from NE and from ESCC in terms of its sensitivity
and specificity.
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CDH13 methylation and mRNA levels in esophageal cancer cell
lines pre- and post-5-Aza-dC treatment
KYSE220 ESCC and OE33 EAC cells were subjected to 5-Aza-
dC treatment. After 5-Aza-dC treatment, the NMV of CDH13 was
diminished and the mRNA level of CDH13 was increased in both
KYSE220 and OE33 cells (Fig. 3).
Discussion
In the current study, we systematically investigated hypermeth-
ylation of the CDH13 gene promoter in cell lines and primary
human esophageal lesions of contrasting histological types and
grades by qMSP. Our results demonstrate that CDH13 promoter
hypermethylation occurs frequently in human EAC, but not in
ESCC. In addition, our data show that CDH13 hypermethylation
increases early during esophageal adenocarcinogenesis, from 0%
in NE to 58.3% in BE, 77.5% in D and 76.1% in EAC. These
results imply that hypermethylation of CDH13 occurs early in
most subjects, that its frequency increases during adenocarcino-
genesis, and that it is tissue-specific (i.e., common in EAC but rare
in ESCC). Further evidence supporting this tissue specificity is
provided by ROC curves, which clearly distinguished EAC from
ESCC. Similarly, support for tissue specificity is evident from the
finding that both CDH13 hypermethylation frequency and mean
CDH13 NMV were significantly higher in EAC than in ESCC. In
addition, the low frequency (19.2%) of CDH13 hypermethylation
in ESCC, as determined in the current study, is consistent with
previous findings by other groups.24,29 Thus, CDH13 hypermeth-
ylation appears to constitute a critical event in only one of the two
esophageal cancer subtypes.
Several studies have suggested that methylation of certain genes
may occur as a field change and may be associated with an
increased risk of malignant progression.17,19,20,30,35 CDKN2A,
ESR1 and MYOD1 were methylated only in BE from patients who
possessed dysplasia or cancer in other regions of their esophagus,
but not in patients with no evidence of progression beyond BE,
while CALCA, MGMT and TIMP3 were methylated more fre-
quently in normal stomach, normal esophageal mucosa and intesti-
nal metaplasia from patients with distant dysplasia or esophageal
cancer than from patients without dysplasia or cancer.35 Previ-
ously, we demonstrated that hypermethylation of p16, RUNX3 and
HPP1 in BE or LGD may represent independent risk factors for
the progression of BE to HGD or EAC.30 Recently, we also found
that both hypermethylation frequency and NMV of the nel-like 1,
tachykinin-1, somatostatin and AKAP12 genes were higher in BE
with accompanying EAC than in BE without accompanying
EAC.17–20 Interestingly, both CDH13 hypermethylation frequency
and level were significantly higher in BE with than without
accompanying EAC in the current study, suggesting that CDH13
is a biomarker of more ominous disease lurking nearby.
In this study, we also correlated CDH13 methylation with clini-
copathologic features. Despite some degree of controversy regard-
ing the length of the BE segment as a predictive factor in BE pro-
gression, it is likely that this clinical parameter is an important
predictor of neoplastic progression. In the Seattle Barrett’s Esoph-
agus Project, BE segment length was not related to cancer risk in a
prospective cohort study of 309 Barrett’s patients (p > 0.2); how-
ever, when patients with HGD at entrance were excluded, a strong
trend was observed, with a 5 cm difference in length associated
FIGURE 2 – Correlation between Barrett’s segment length and CDH13 hypermethylation. (a), Normalized methylation value (NMV) of
CDH13 was significantly higher in long-segment BE (LSBE, mean5 0.4071) than in short-segment BE (SSBE, mean5 0.131; p5 0.0032, Stu-
dent’s t-test). (b), Positive CDH13 hypermethylation status was significantly correlated with BE segment length (p5 0.0005, Student’s t-test).
FIGURE 3 – CDH13 methylation level and mRNA expression in
esophageal cancer cell lines after treatment with the demethylating
agent 5-aza-20-deoxycytidine (5-Aza-dC). KYSE220 and OE33 EAC
cells were subjected to 5-Aza-dC treatment. In both cell lines, after 5-
Aza-dC treatment, the NMV of CDH13 was diminished, while the
normalized mRNA value (NRV) of CDH13 was increased.
2334 JIN ET AL.
with a 1.7-fold increase in cancer risk (95% CI, 0.8- 3.8-fold).34
Significant differences in the frequency of both dysplasia and
EAC were observed between SSBE and LSBE, at 8.1% vs. 24.4%
for dysplasia (p < 0.0001) and 0% vs. 15.4% for EAC (p <
0.0005).36 In a comprehensive prospective study of 889 consecu-
tive patients, the prevalence of dysplasia and cancer differed sig-
nificantly in patients with SSBE vs. LSBE.37 More recently, a sig-
nificantly increased risk of progression to HGD or EAC with
LSBE after a mean follow-up of 12.7 years was reported.38 In our
previous studies, the nel-like 1, tachykinin-1, somatostatin and
AKAP12 genes were significantly more hypermethylated in LSBE
than in SSBE.17–20 Notably, in the current study, CDH13 methyla-
tion also showed a strong relationship to BE segment length. The
mean NMV of CDH13 was significantly higher in LSBE than in
SSBE. Similarly, the length of the BE segment was significantly
greater in specimens with methylated than with unmethylated
CDH13 promoters. Thus, CDH13 hypermethylation may consti-
tute a molecular correlate of BE segment length, as well as a har-
binger of nearby neoplastic disease. These results also suggest that
epigenetic alterations, which may account for some of the biologic
behavior of BE, clearly differ between LSBE and SSBE, suggest-
ing a need for further large-scale studies.
In the current study, the mean NMV in dysplasia was higher
than in EAC. This finding could have resulted from either differ-
ences in sample sizes between these two groups, or from differen-
tial contamination by nonneoplastic cells.
In accordance with previous findings in other primary cancer
cell types,28 we observed that methylation of CDH13 in EAC and
ESCC cancer cell lines was associated with silenced or reduced
expression of CDH13 mRNA. Treatment with 5-Aza-dC restored
mRNA expression and reversed CDH13 methylation in these cells.
Restoration of CDH13 mRNA expression by demethylating agent
treatment implies that DNA hypermethylation was responsible for
silencing of CDH13.
In summary, findings of the current study suggest that hyper-
methylation of the CDH13 promoter is a common event in human
esophageal adenocarcinogenesis, occurs early during Barrett’s-
associated esophageal carcinogenesis, and is associated with clini-
cal risk factors of progression. In addition, CDH13 hypermethyl-
ation is uncommon in human ESCC, thus making it a potential
cell type-specific biomarker for EAC. Further large-scale prospec-
tive longitudinal validation studies of this alteration as a predictive
biomarker for EAC development are warranted by these data.
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